1. Home
  2. DECK vs BIIB Comparison

DECK vs BIIB Comparison

Compare DECK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deckers Outdoor Corporation

DECK

Deckers Outdoor Corporation

HOLD

Current Price

$99.39

Market Cap

12.4B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DECK
BIIB
Founded
1973
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
24.2B
IPO Year
1993
1991

Fundamental Metrics

Financial Performance
Metric
DECK
BIIB
Price
$99.39
$181.61
Analyst Decision
Buy
Buy
Analyst Count
21
23
Target Price
$121.63
$176.48
AVG Volume (30 Days)
3.5M
1.9M
Earning Date
10-23-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
18.83
N/A
EPS
6.75
10.97
Revenue
$5,244,323,000.00
$10,065,900,000.00
Revenue This Year
$9.84
$3.61
Revenue Next Year
$7.36
N/A
P/E Ratio
$14.77
$16.52
Revenue Growth
12.62
4.77
52 Week Low
$78.91
$110.04
52 Week High
$223.98
$185.17

Technical Indicators

Market Signals
Indicator
DECK
BIIB
Relative Strength Index (RSI) 67.87 72.92
Support Level $81.40 $174.53
Resistance Level $86.09 $182.94
Average True Range (ATR) 3.00 5.22
MACD 2.31 0.25
Stochastic Oscillator 99.97 83.54

Price Performance

Historical Comparison
DECK
BIIB

About DECK Deckers Outdoor Corporation

Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has nearly 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: